Insider · CIK 0001781549
James Loerop
officer
Files at ACRS (Aclaris Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +11,250 | - | - | 96,503 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +7,500 | - | - | 104,003 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +14,750 | - | - | 118,753 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -15,447 | $2.48 | $38k | 103,306 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -11,250 | $0.00 | $0 | 11,250 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Resticted Stock Unitsderivative | -7,500 | $0.00 | $0 | 15,000 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -14,750 | $0.00 | $0 | 44,250 | Feb 4, 2025 |
| Feb 3, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +83,500 | $0.00 | $0 | 83,500 | Feb 4, 2025 |
| Feb 3, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
| Dec 31, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +73,750 | - | - | 107,767 | Jan 3, 2025 |
| Dec 31, 2024 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -32,089 | $2.48 | $80k | 75,678 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +18,150 | - | - | 93,828 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -8,575 | $2.48 | $21k | 85,253 | Jan 3, 2025 |
| Dec 31, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -73,750 | $0.00 | $0 | 73,750 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +55,000 | $0.00 | $0 | 55,000 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -18,150 | $0.00 | $0 | 36,850 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.